Morgan Stanley’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-252,730
| Closed | -$13.9M | – | 8212 |
|
|
2022
Q2 | $13.9M | Buy |
252,730
+157,574
| +166% | +$8.27M | ﹤0.01% | 2691 |
|
|
2022
Q1 | $3.05M | Buy |
95,156
+84,950
| +832% | +$2.44M | ﹤0.01% | 4187 |
|
|
2021
Q4 | $222K | Buy |
10,206
+10,173
| +30,827% | +$224K | ﹤0.01% | 6012 |
|
|
2021
Q3 | $1K | Buy |
33
+23
| +230% | +$460 | ﹤0.01% | 7895 |
|
|
2021
Q2 | $0 | Hold |
10
| – | – | ﹤0.01% | 7889 |
|
|
2021
Q1 | $0 | Sell |
10
-992
| -99% | -$15.7K | ﹤0.01% | 7629 |
|
|
2020
Q4 | $16K | Sell |
1,002
-9,248
| -90% | -$128K | ﹤0.01% | 6510 |
|
|
2020
Q3 | $109K | Buy |
10,250
+9,874
| +2,626% | +$118K | ﹤0.01% | 5392 |
|
|
2020
Q2 | $4K | Sell |
376
-155
| -29% | -$1.92K | ﹤0.01% | 6366 |
|
|
2020
Q1 | $5K | Buy |
531
+175
| +49% | +$2.29K | ﹤0.01% | 6240 |
|
|
2019
Q4 | $5K | Buy |
356
+345
| +3,136% | +$4.5K | ﹤0.01% | 6405 |
|
|
2019
Q3 | $0 | Sell |
11
-50
| -82% | -$957 | ﹤0.01% | 6845 |
|
|
2019
Q2 | $1K | Sell |
61
-21,260
| -100% | -$1.03M | ﹤0.01% | 6598 |
|
|
2019
Q1 | $1.46M | Sell |
21,321
-1,576
| -7% | -$101K | ﹤0.01% | 3849 |
|
|
2018
Q4 | $1.21M | Sell |
22,897
-1,916
| -8% | -$122K | ﹤0.01% | 4140 |
|
|
2018
Q3 | $1.69M | Buy |
24,813
+2,518
| +11% | +$228K | ﹤0.01% | 4148 |
|
|
2018
Q2 | $2.64M | Buy |
22,295
+14,780
| +197% | +$1.48M | ﹤0.01% | 3821 |
|
|
2018
Q1 | $622K | Buy |
7,515
+7,465
| +14,930% | +$846K | ﹤0.01% | 4870 |
|
|
2017
Q4 | $7K | Buy |
+50
| New | +$4.81K | ﹤0.01% | 6292 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | – | – | 6659 |
|
|
2017
Q2 | $0 | Sell |
1
-60
| -98% | -$3.06K | ﹤0.01% | 6690 |
|
|
2017
Q1 | $4K | Sell |
61
-402
| -87% | -$23.4K | ﹤0.01% | 6397 |
|
|
2016
Q4 | $28K | Buy |
463
+377
| +438% | +$23.5K | ﹤0.01% | 5913 |
|
|
2016
Q3 | $6K | Sell |
86
-688
| -89% | -$53.2K | ﹤0.01% | 6214 |
|
|
2016
Q2 | $62K | Buy |
774
+499
| +181% | +$95.1K | ﹤0.01% | 5451 |
|
|
2016
Q1 | $73K | Buy |
275
+174
| +172% | +$55.6K | ﹤0.01% | 5457 |
|
|
2015
Q4 | $61K | Sell |
101
-2,089
| -95% | -$1.41M | ﹤0.01% | 5633 |
|
|
2015
Q3 | $1.8M | Buy |
+2,190
| New | +$2.47M | ﹤0.01% | 3613 |
|
Other funds holding SRRA
Morgan Stanley's SRRA Position: Q3 2022 in Review
Morgan Stanley sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 252,730 shares — an estimated $13.9M sold.
Morgan Stanley first reported a position in SRRA in Q3 2015 and held it in 27 quarters. The position peaked at $13.9M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Morgan Stanley reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Morgan Stanley sold 252,730 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $13.9M.
- Morgan Stanley first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 27 quarters.
- Morgan Stanley's Sierra Oncology, Inc. Common Stock position peaked at $13.9M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.